We are thrilled to announce the commencement of construction of our new Active Pharmaceutical Ingredient (API) manufacturing facility near our existing unit, Macsen Drugs in RIICO Industrial Area, Gudli, Udaipur, Rajasthan, India. This strategic growth represents a major advancement in our dedication to improving manufacturing capacities to meet the ever-changing demands of the pharmaceutical sector.
Spanning over an expansive area of 25,000 square meters, the new facility is five times larger in land area compared to our current infrastructure at Macsen Drugs, which is our US FDA Inspected, TGA-GMP and WHO-GMP certified manufacturing unit. Designed to support scalability and operational efficiency, it will include multiple API production blocks capable of handling diverse and advanced manufacturing processes for APIs for various therapeutic applications.
Phase I Investment and Development Highlights
Macsen plans to invest approximately INR 75 crore in the initial phase of development. Key components of Phase I include:
Two API Production Blocks: Dedicated to the manufacturing of high-quality APIs, these blocks will be equipped with cutting-edge technology to ensure precision, quality, and compliance with global standards. These blocks will have multistorey production facility and a combined reactor capacity of 100 KL (both stainless steel & glass-lined reactors).
State-of-the-Art R&D Center: A new dedicated R&D center will be established over an area of 15,000 sq ft. to advance our synthesis, analytical & research capabilities. The center will facilitate our innovation initiatives, encouraging the development of pharmaceutical products and procedures to satisfy the ever-changing demands of the global healthcare sector.
Advanced Pilot Plant: The facility will include a pilot plant equipped with comprehensive process equipment and technologies. It will enable:
- Pilot-scale production of APIs & Intermediates
- A dedicated cGMP (Good Manufacturing Practice) section for piloting developed APIs
- Commercial production of low-volume, pre-clinical and clinical trial APIs
Expansion of Manufacturing Capabilities
- We have a plan to install a special production line for manufacturing & performing corrosive chemistries with Hastelloy, Halar-coated equipments, etc.
- We also plan to expand our hydrogenation reaction capabilities.
Timeline and Future Vision
We aim to commence production activities at this new facility by the end of 2025. This expansion underscores our long-term vision to strengthen our manufacturing footprint and enhance our capacity to deliver high-quality, cost-effective pharmaceutical solutions to the global market.
Media Coverage
The Economic Times – Macsen Labs group commences construction of new API manufacturing facility
ANI News – Macsen Labs Group Commences Construction of New API Manufacturing Facility
Yahoo Finance – Macsen Labs Group Commences Construction of New API Manufacturing Facility
Business Standard – Macsen Labs Group Commences Construction of New API Manufacturing Facility
Macsen Labs Group Breaks Ground on New API Manufacturing Facility